Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA), Prof Karim Fizazi (Institut Gustave Roussy, Villejuif, France), Prof Kim Chi (Vancouver Prostate Centre, Vancouver, Canada) and Prof Matthew Smith (Harvard Medical School, Boston, USA) discuss the updates in mHSPC from the ASCO GU 2022 meeting.
They discuss the data from the LATITUDE, ARCHES, TITAN, ARASENS and PEACE-1 trials.
Initially, Prof Smith gives an overview of the ARASENS trial and what is the overall survival with darolutamide in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer patients. Then Prof Fizazi explains the data from PEACE-1 trial.
Prof Chi talks about the association between patient-reported outcomes (PROs) and changes in prostate-specific antigen in patients with advanced prostate cancer treated with apalutamide in the SPARTAN and TITAN studies.
He also discusses the effect of prior docetaxel treatment on efficacy and safety of apalutamide plus androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.
They further discuss the overall survival in patients with mHSPC treated with enzalutamide + androgen deprivation therapy by high or low disease volume and progression to mHSPC or de novo mHSPC.
Prof Efstathiou concludes by summarising all the updates so far and what it means for the future treatment of mHSPC patients.